Stakeholder Opinions: Primary Brain Cancer

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-07-02

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Incidence of primary brain cancer across the seven major markets in 2007 is estimated to be 47,000. Over half of these cases will be glioblastoma multiforme, for which survival prospects are dismal. The median survival for this group of patients is 1.2 years and only 27% of patients are alive after two years. The level of unmet need is therefore high in this disease.


Scope

  • Incidence, diagnosis and treatment of primary brain cancer, including treatment regimens by stage and ongoing controversies
  • Unmet needs, emerging trends and commercial incentives in primary brain cancer
  • Examination of pipeline activity and potential future opportunities for drug developers
  • Stakeholder opinions and interview transcripts based on qualitative interviews with six opinion leaders from the US and Europe


    • Report Highlights
    The standard set by drugs that have been approved for primary brain cancer is low; therefore drugs only need to demonstrate relatively modest improvements in survival to be adopted by physicians. A substantial opportunity also exists for a second-line chemotherapy to enter the primary brain cancer market.

    Several molecular markers have been associated with glioma. It is possible that these markers could significantly affect treatment patterns, resulting in a stratified glioma market. Targeted therapies could be reserved solely for patients whose molecular profile indicates that they will benefit from such drugs.

    The potential of Phase III pipeline drugs is limited by factors such as low efficacy and complicated delivery methods. Of the drugs in the Phase II pipeline for glioma, targeted therapies show most potential. In particular, angiogenesis inhibitors have considerable commercial potential because they may reduce the co-morbidity edema.


    Reasons to Purchase

  • Identify the limitations of current therapy available to primary brain cancer patients and the potential of future therapy
  • Understand current epidemiological trends in primary brain cancer and ongoing treatment controversies
  • Assess the opportunities for innovative targeted therapies in primary brain cancer, particularly in recurrent disease

    • Table of Contents

    Other users found this report page using the following search terms: brain cancer glioma glioma brain glioblastoma grade multiforme 4 cancer prognosis treatment tumor

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.